Explore the latest news from Khondrion and its team.
NIJMEGEN, the Netherlands – 1 June 2022: Khondrion (or the “Company”), a clinical stage biopharmaceutical company discovering and developing...
NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting...
Enabling continued treatment in 52-week multi-centre study for patients who have completed ongoing KHENERGYZE Phase IIb study investigating...
NIJMEGEN, the Netherlands – 14 October 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
NIJMEGEN, the Netherlands – 26 August 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces the...
In November 2018, Jan Smeitink, founder and CEO of Khondrion attended the 24th Annual BIO-Europe conference in Copenhagen, Denmark. He spoke to Mike...
Khondrion, the clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, starts 2019 with the...
In July 2018 Khondrion was awarded €2.3M funding from the EU Horizon 2020 Research and Innovation programme to progress clinical development of KH176, its lead pipeline asset. Prof. Dr. Jan Smeitink, Chief Executive Officer of Khondrion, talks to Catalyze®, who collaborated with Khondrion on the company’s successful funding submission, about his ambitions for Khondrion and the mitochondrial disease research his team is leading.
Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, today announced the publication of a scientific article reporting on the development and unique mode of action of KH176, a clinical-stage drug candidate for the treatment of mitochondrial diseases.
Khondrion presents Phase II KHENERGY trial data. Data supporting Phase III development of KH176 in mitochondrial disease.
Read the interview on pharmaboardroom.com Interview: Jan Smeitink – CEO, Khondrion, The Netherlands Jan Smeitink, CEO of...
